JUVELOOK in Seoul

No. JUVELOOK is NOT cleared by the US FDA as an injectable. It is MFDS-approved as a medical device in Korea (since approximately 2021) and CE-marked in the EU. Several Gangnam clinic marketing pages incorrectly claim FDA approval — likely confusion with Sculptra (PLLA, manufactured by Galderma), which is FDA-approved and is a different molecule (L-isomer only, not the D,L racemic mixture in JUVELOOK). Honest regulatory framing is part of board-certified Anti-Aging specialist standards.

Both are biostimulators that trigger fibroblast-driven collagen synthesis, but they differ in molecule, particle size, and formulation. Sculptra uses pure L-isomer PLLA (~40-63 μm crystalline microspheres), is FDA-approved with 25+ years of clinical evidence, and historically required pre-hydration. JUVELOOK uses D,L racemic PDLLA (~20 μm amorphous microspheres, per Jang 2026 PMID 42049428) pre-mixed with HA carrier for same-day reconstitution and immediate softening. An independent SNU/Sookmyung mouse comparator (PMID 42049428) showed PLLA produced greater collagen area than PDLLA at 12 weeks — so 'JUVELOOK better than Sculptra' is not supported by published data. The honest difference is formulation engineering: JUVELOOK offers faster reconstitution, smaller particles, and HA-driven immediate softening; Sculptra offers a longer global evidence track record.

Same active ingredients (PDLLA + HA) but different formulations. Base JUVELOOK uses smaller particles for superficial-to-mid-dermal skin boosting (texture, fine lines, periorbital). JUVELOOK Volume — sold internationally as LENISNA — has approximately 4× higher PDLLA dose (~170 mg vs ~42.5 mg) and a thicker HA carrier for deep-dermal or subcutaneous volumization (mid-face, deep tear trough, jawline). Variant clarity matters: JUVELOOK Volume and LENISNA on different clinic menus are the same product.

Delight's induction protocol is 3 sessions at about 1-month (4-week) intervals — within the 3-6-week range reported in published JUVELOOK papers (tear trough: PMID 42098500; lower eyelid: PMID 40017393; pore reduction: PMID 40469551). The HA carrier provides subtle same-day softening; collagen-driven change becomes visible at 6-12 weeks and continues developing for several months. There is currently no published JUVELOOK study extending past 12 months — durability beyond that is not yet established by peer-reviewed data.

Rare but serious: vascular occlusion, including blindness, from inadvertent intravascular injection — particularly in glabellar, periorbital, and forehead zones. The Lau 2025 expert consensus on PDLLA-HA200-induced visual impairment (PMID 41359890) is the authoritative safety document; clinic protocol should reflect its key safe-injection messages (cannula for high-risk zones, hyaluronidase emergency kit, anatomy-based depth control). Common transient risks include swelling, bruising, and mild erythema (~7-43% across published series); rare late-onset nodules have been documented — one published JUVELOOK tear-trough nodule case fully resolved with monopolar RF (Seo 2024, PMID 39283001).